Foundation Medicine (NASDAQ: FMI) and Jaguar Health (NASDAQ:JAGX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Valuation and Earnings
This table compares Foundation Medicine and Jaguar Health’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Foundation Medicine||$152.90 million||19.92||-$161.46 million||($4.50)||-18.36|
|Jaguar Health||$140,000.00||129.43||-$14.73 million||($0.66)||-0.30|
Risk and Volatility
Foundation Medicine has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Jaguar Health has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.
Insider & Institutional Ownership
29.2% of Foundation Medicine shares are owned by institutional investors. Comparatively, 12.4% of Jaguar Health shares are owned by institutional investors. 2.7% of Foundation Medicine shares are owned by insiders. Comparatively, 3.3% of Jaguar Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Foundation Medicine and Jaguar Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for Foundation Medicine and Jaguar Health, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Foundation Medicine currently has a consensus target price of $70.50, suggesting a potential downside of 14.65%. Jaguar Health has a consensus target price of $2.00, suggesting a potential upside of 902.51%. Given Jaguar Health’s stronger consensus rating and higher probable upside, analysts clearly believe Jaguar Health is more favorable than Foundation Medicine.
Jaguar Health beats Foundation Medicine on 10 of the 14 factors compared between the two stocks.
Foundation Medicine Company Profile
Foundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).
Jaguar Health Company Profile
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.